Concepedia

Author

Y. Yanagita

Saitama Cancer Center

Also Known As

Y Yanagita, Y. Yanagita, Yorihide Yanagita, Yusei Yanagita, Yuya Yanagita

39

Publications

952

Citations

10

H-Index

28

Concepts

All Affiliations

Saitama Cancer CenterKyoto University HospitalAichi Cancer CenterGunma UniversityUniversity of Tsukuba
YY

About

Y. Yanagita is an author at Saitama Cancer Center specializing in breast cancer, medicine, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

146

2

Engineering

1

1

31

3

Health Sciences

1

1

45

4

Cell Biology

1

1

22

5

Obstetrics

1

1

11

Y. Yanagita

×

8

Publications

878

Citations

8

H-Index

YearCitations

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André,

Annals of Oncology

2021

689

Abstract S1-07: A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04)

Masakazu Toi, SJ Lee, Shoichiro Ohtani,

Cancer Research

2016

45

Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study)

Masahiro Takada, Hiroshi Ishiguro, Shigenori E. Nagai,

Breast Cancer Research and Treatment

2014

37

Molecular analysis of the h-warts/LATS1 gene in human breast cancer.

Nobuhiro Morinaga, Yoshinori Shitara, Y. Yanagita,

International Journal of Oncology

2000

31

Absence of mutations in the analysis of coding sequences of the entire transforming growth factor-beta type II receptor gene in sporadic human breast cancers.

Seiichi Takenoshita, Akira Mogi, M Tani,

Oncology Reports

1998

28

A Study on Telomerase Activity and Prognosis in Breast Cancer

Morihiko Kimura, T Koida, Y. Yanagita

Medical Oncology

2003

22

Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial

Norikazu Masuda, Masakazu Toi, Naomi Yamamoto,

Breast Cancer

2018

15

Abstract GS3-04: A prospective randomized multi-center open-label phase III trial of extending aromatase-inhibitor adjuvant therapy to 10 years - Results from 1697 postmenopausal women in the N-SAS BC 05 trial: Arimidex extended adjuvant randomized study (AERAS)

Shoichiro Ohtani, Kotaro Iijima, Kenji Higaki,

Cancer Research

2019

11

Page 1